Ultragenyx Pharmaceutical Inc. 8-K

What Happened On May 5, 2026, Ultragenyx Pharmaceutical Inc. (RARE) issued a press release reporting its financial results for the three months ended March 31, 2026. The company furnished the press release as Exhibit 99.1 to a Current Report on Form 8-K (Item 2.02), which was signed by Howard Horn, Executive Vice President and Chief Financial Officer, on May 5, 2026.

Key Details

• Filing date: May 5, 2026; reporting period: quarter ended March 31, 2026.
• Item reported: 2.02 (Results of Operations and Financial Condition); press release furnished as Exhibit 99.1.
• Exhibit listed: 99.1 — Press Release dated May 5, 2026.
• Form 8-K signed by Howard Horn, EVP & CFO, on behalf of Ultragenyx.

Why It Matters This 8-K notifies investors that Ultragenyx publicly released its quarterly financial results; the press release (Exhibit 99.1) is the place to find revenue, earnings, cash position, and any guidance or operational updates. Retail investors should read the furnished press release and subsequent SEC filings (e.g., 10-Q) to see the actual financial figures and assess impacts on valuation, cash runway, and program funding. The 8-K itself confirms timely disclosure but does not replace the detail contained in the press release and formal financial statements.